A contingent value right (CVR) is a contractual promise, handed to target shareholders in a takeover, to pay extra cash later if a named milestone is hit before a deadline; miss the milestone or the date and the CVR pays nothing. Buyers use CVRs to bridge a price gap: the seller believes in a drug, a product or a revenue target, the buyer will not pay for it upfront, so part of the price becomes conditional. In 2026 the structure showed up in large biotech deals and in a small-cap tech take-private that TTFY covered from announcement to close.
How a CVR works
A CVR is created by a CVR agreement that the buyer, the target and a rights agent sign at or before closing. Three terms decide what it is worth:
- The milestone. Usually a regulatory approval, a sales threshold or a revenue figure, defined precisely in the agreement.
- The deadline. The milestone must be met by a set date or within set calendar years. After that, the right expires worthless.
- The payout. A fixed amount per CVR, a ladder of amounts, or a formula.
Most CVRs are non-transferable: the holder can collect but cannot sell. Apellis's tender documents put it plainly: the CVRs "are contractual rights only and not transferable except under certain limited circumstances, will not be certificated or evidenced by any instrument and will not be registered with the SEC or listed for trading." A tradable CVR is the exception: it is registered and can trade after closing, which gives holders an exit and gives the market a live price for the milestone. Every 2026 example below is the non-transferable kind, so the only way to cash out is to wait.
The buyer usually promises some level of effort toward the milestone, not the milestone itself. In the Biogen–Apellis CVR, Biogen agreed to use "Commercially Diligent Efforts," and the filing adds that this "does not provide any guarantee that either of the milestones will be achieved."
Worked example: three 2026 CVR deals
All terms below come from the companies' SEC filings and press releases.
| Deal | Cash per share | CVR max | Milestone | Deadline | Status |
|---|---|---|---|---|---|
| Gilead buys Arcellx ($ACLX) | $115.00 | $5.00 | Cumulative global net sales of anito-cel of at least $6.0 billion | From launch through the end of 2029 | Closed April 28, 2026 |
| Biogen buys Apellis ($APLS) | $41.00 | $4.00 | $2.00 at $1.5 billion of annual SYFOVRE net sales; $2.00 at $2.0 billion | Any year 2027–2030 for the first; 2027–2031 for the second | Closed May 14, 2026 |
| Transom buys SoundThinking ($SSTI) | $8.00 | $3.00 | 2027 revenue from ShotSpotter and SafePointe of $73.5 million to $87 million, sliding scale | Fiscal 2027 (plus certain 2027 revenue recognized in 2028) | Closed November 18, 2026 |
Gilead–Arcellx is the simplest shape: one milestone, one payment, all or nothing. According to Gilead's closing release, the $115 cash plus $5 CVR represented "a total implied equity value of approximately $7.8 billion at the time of closing." If anito-cel's cumulative sales reach $6.0 billion by the end of 2029, holders get $5; short of that, they get nothing.
Biogen–Apellis splits the right into two $2.00 pieces. Per the Apellis Schedule 14D-9, if the $1.5 billion milestone "is not met prior to December 31, 2030 but the net sales milestone 2 is achieved during the 2031 calendar year, then the net sales milestone 2 will be worth $4.00 per CVR." Each milestone pays once. The same filing shows how the CVR was negotiated: Biogen's October 2, 2025 proposal was $37.50 cash plus a $3.00 CVR tied to $1 billion of annual SYFOVRE sales by 2028. The final deal put more into upfront cash ($41.00) and raised the CVR ceiling to $4.00, but set higher sales hurdles.
Transom–SoundThinking uses a ladder. Per the September 29 announcement, the CVR pays $0.50 if qualifying 2027 revenue reaches $73.5 million, plus $0.05 for every $0.5 million above that through $75.5 million, plus $0.05 for every $0.25 million above $75.5 million through $87 million. The ladder adds up exactly:
- $73.5 million: $0.50
- $75.5 million: (75.5 − 73.5) ÷ 0.5 = 4 steps × $0.05 = $0.20, so $0.70 total
- $87 million: (87 − 75.5) ÷ 0.25 = 46 steps × $0.05 = $2.30, so $0.70 + $2.30 = $3.00
The upfront $8.00 was a 46% premium to the $5.47 close on September 28, 2026 ($8.00 ÷ $5.47 = 1.46). With the full CVR, the $11.00 total would be a 101% premium ($11.00 ÷ $5.47 = 2.01). TTFY covered the announcement in SoundThinking Buyout Offers $8 Cash and Up to $3 CVR per Share. The tender offer expired November 17 with about 69.5% of shares tendered, and the merger closed November 18.
How to value a CVR
The standard method is a probability-weighted, discounted payout:
CVR value = sum over each milestone of (probability of hitting it × payout) ÷ (1 + discount rate)^(years until payment)
Hypothetical demonstration only, not an estimate for any real deal: take a single $5.00 milestone, assume a 35% chance it is hit, payment in 3.5 years, and a 12% annual discount rate. Expected payout is 0.35 × $5.00 = $1.75. The discount factor is 1.12^3.5 = 1.487. Value = $1.75 ÷ 1.487 = about $1.18 per CVR. Change one input and the answer moves a lot: at a 20% probability the same math gives $1.00 ÷ 1.487 = about $0.67.
For a ladder like SoundThinking's, the same math runs across a range of revenue outcomes, each with its own probability and payout. Bankers do this work with management's own probability estimates. Apellis's adviser Evercore, for example, relied "upon the assessment of management of Apellis as to the probability of achieving each milestone," and expressed no view on those odds.
The market gives a rough read too. In its last trading session before the deal closed, November 17, 2026, $SSTI closed at $8.24, or $0.24 above the $8.00 cash. That suggests traders valued the CVR at roughly $0.24, or 8% of its $3.00 maximum ($0.24 ÷ $3.00 = 0.08). That figure bundles odds, timing and the payout ladder into one number, and it is a market price, not a forecast.
Common mistakes with CVRs
- Adding the CVR at face value. "Up to $11.00 per share" is a ceiling, not a price. The cash is the only certain part.
- Ignoring the deadline. A milestone reached after the deadline generally pays nothing. Apellis's $4.00 catch-up in 2031 is an exception, and it is spelled out in the contract.
- Misreading the metric. SoundThinking's CVR counts revenue from ShotSpotter and SafePointe only, not total company revenue. Arcellx's counts cumulative global net sales of one therapy.
- Assuming the buyer must hit the target. Effort clauses promise effort, not results. After closing, the buyer runs the business that decides whether the target is met.
- Assuming a sale is possible. Non-transferable CVRs cannot be sold, so the money stays tied up until the milestone is hit or the right expires.
- Forgetting the deal must close first. A CVR exists only if the merger completes. Signed deals do fail; TTFY's H&R REIT coverage follows a C$6.7 billion sale that unitholders voted down on November 13, 2026.
- Overlooking amendment rules. Biogen can amend the Apellis CVR with consent from holders of at least 32.5% of the CVRs, and some changes need 75%.
CVRs often sit next to other deal protections. A buyer's walk-away cost is covered in the reverse termination fee explainer, and the window in which a target can shop for a better offer is covered in go-shop period. Tax treatment of CVR payments varies; this is general information, not tax or legal advice. More deal coverage is on the TTFY homepage.
Bull/Bear Verdict
Bull Case: A CVR tends to favor holders when the milestone sits close to the business's existing trajectory, the deadline leaves room, and the payout is a ladder rather than all-or-nothing. Holders keep a slice of the upside they would otherwise give up for cash today.
Bear Case: The buyer controls the asset after closing, the metric is narrow, and one missed deadline can zero the right. Non-transferable CVRs lock holders in for years, and a roughly $0.24 market value on SoundThinking's $3.00 CVR shows how heavily traders can discount a promise.
FAQ
Is a contingent value right the same as a stock?
No. A CVR carries no voting or dividend rights. The Apellis filing says the CVRs "will not represent any equity or ownership interest" in Biogen, Apellis or their affiliates. It is a contract to receive cash if a condition is met.
Can a CVR be sold?
Only if it is a tradable CVR. The 2026 CVRs from Gilead–Arcellx, Biogen–Apellis and Transom–SoundThinking were all non-transferable, so holders collect if the milestone is hit and otherwise get nothing.
What happens if the milestone is missed?
The CVR expires without payment. For former Arcellx holders, the $5.00 pays only if anito-cel's cumulative global net sales reach $6.0 billion by the end of 2029.
How do traders estimate what a CVR is worth?
They multiply each payout by its estimated probability and discount it for the years until payment. While the target still trades, the gap between the share price and the cash consideration gives a rough market value, as with $SSTI's $0.24 premium to $8.00 on November 17, 2026.